Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Hemogenyx Pharmaceuticals logo
GBX 1.32
-0.02 (-1.49%)
(As of 11/1/2024 ET)

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Key Stats

Today's Range
1.30
1.40
50-Day Range
1.13
1.75
52-Week Range
1.08
7.13
Volume
2.12 million shs
Average Volume
9.05 million shs
Market Capitalization
£17.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HEMO Stock News Headlines

Musk warns humanity: “Obsolete”
The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.
See More Headlines

HEMO Stock Analysis - Frequently Asked Questions

Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 at the start of the year. Since then, HEMO stock has decreased by 42.4% and is now trading at GBX 1.33.
View the best growth stocks for 2024 here
.

Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter.

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
9/30/2020
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
£-5,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Outstanding Shares
1,340,000,000
Free Float
N/A
Market Cap
£17.76 million
Optionable
Not Optionable
Beta
3.14
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (LON:HEMO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners